UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management

International journal of molecular sciences, 2018-01, Vol.19 (1), p.182

2018

Volltextzugriff (PDF)

Impact of Resident Involvement in Surgery (IRIS-NSQIP): Looking at the Bigger Picture Based on the American College of Surgeons-NSQIP Database

Journal of the American College of Surgeons, 2016, Vol.222 (1), p.30-40

2016

Volltextzugriff (PDF)

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

Haematologica (Roma), 2024-09, Vol.109 (9), p.2864

2024

Volltextzugriff (PDF)

Iron overload in thalassemia: different organs at different rates

Hematology, 2017-12, Vol.2017 (1), p.265-271

2017

Volltextzugriff (PDF)

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood cancer journal (New York), 2024-02, Vol.14 (1), p.32-32, Article 32

2024

Volltextzugriff (PDF)

Minimal residual disease in Philadelphia‐positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing

American journal of hematology, 2023-08, Vol.98 (8), p.1168-1170

2023

Volltextzugriff (PDF)

The evolution of frontline therapy for adult Philadelphia‐positive acute lymphoblastic leukemia: Giant strides and ongoing challenges

American journal of hematology, 2023-03, Vol.98 (3), p.374-376

2023

Volltextzugriff (PDF)

Accelerated and blast phase myeloproliferative neoplasms

Best practice & research. Clinical haematology, 2022-06, Vol.35 (2), p.101379-101379, Article 101379

2022

Volltextzugriff (PDF)

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study

Blood cancer journal (New York), 2021-03, Vol.11 (3), p.43-43, Article 43

2021

Volltextzugriff (PDF)

How I treat non-transfusion-dependent β-thalassemia

Blood, 2023-09, Vol.142 (11), p.949-960

2023

Volltextzugriff (PDF)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes

Blood cancer journal (New York), 2021-03, Vol.11 (3), p.54-54, Article 54

2021

Volltextzugriff (PDF)

Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene

Wisconsin medical journal (Madison, Wis.), 2024-05, Vol.123 (2), p.131-134

2024

Volltextzugriff (PDF)

Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis

Blood reviews, 2023-03, Vol.58, p.101015-101015, Article 101015

2023

Volltextzugriff (PDF)

A land in agony: COVID‐19, economic collapse, political corruption, and a deadly blast

American journal of hematology, 2021-01, Vol.96 (1), p.E1-E2

2021

Volltextzugriff (PDF)

The Lebanese healthcare sector: The point of exsanguination

American journal of hematology, 2021-11, Vol.96 (11), p.E403-E404

2021

Volltextzugriff (PDF)

67-Year-Old Woman With Diarrhea and Weight Loss

Mayo Clinic proceedings, 2022-02, Vol.97 (2), p.364-369

2022

Volltextzugriff (PDF)

Immunotherapy-associated Autoimmune Hemolytic Anemia

Hematology/oncology clinics of North America, 2022-04, Vol.36 (2), p.365-380

2022

Volltextzugriff (PDF)

Morbidities in non-transfusion-dependent thalassemia

Annals of the New York Academy of Sciences, 2016-03, Vol.1368 (1), p.82-94

2016

Volltextzugriff (PDF)

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

Cancers, 2021-12, Vol.13 (24), p.6385

2021

Volltextzugriff (PDF)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

Cancer Drug Resistance, 2021-01

2021

Volltextzugriff (PDF)

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

British journal of haematology, 2024-04, Vol.204 (4), p.1232-1237

2024

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Englisch
(81)
Französisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(55)
Humans
(38)
Hematology
(35)
Oncology
(16)
Male
(15)
Female
(14)
Middle Aged
(14)
Adult
(13)
Aged
(10)
Thalassemia
(10)
Acute Myeloid Leukemia
(8)
Retrospective Studies
(8)
Biomedical And Life Sciences
(6)
Iron Chelating Agents - Therapeutic Use
(6)
Leukemia, Myeloid, Acute - Genetics
(6)
Beta-Thalassemia - Therapy
(5)
Cancer Research
(5)
Covid-19
(5)
Iron
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management

Impact of Resident Involvement in Surgery (IRIS-NSQIP): Looking at the Bigger Picture Based on the American College of Surgeons-NSQIP Database

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience

Prognostic impact of ‘multi-hit’ versus ‘single hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases

Iron overload in thalassemia: different organs at different rates

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Minimal residual disease in Philadelphia‐positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing

The evolution of frontline therapy for adult Philadelphia‐positive acute lymphoblastic leukemia: Giant strides and ongoing challenges

Accelerated and blast phase myeloproliferative neoplasms

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study

How I treat non-transfusion-dependent β-thalassemia

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes

Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene

Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis

A land in agony: COVID‐19, economic collapse, political corruption, and a deadly blast

The Lebanese healthcare sector: The point of exsanguination

67-Year-Old Woman With Diarrhea and Weight Loss

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Immunotherapy-associated Autoimmune Hemolytic Anemia

Morbidities in non-transfusion-dependent thalassemia

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

Suchergebnisse filtern